entertainment -WSS

entertainment

author：comprehensive 2025-09-30 00:45:36 - browse：7529

Yichuan Cao/Sipa USA via AP Images

Gilead Sciences said Monday that Trodelvy, its “smart-bomb” medicine that combines an antibody with chemotherapy, did not significantly extend the lives of patients with metastatic non-small cell lung cancer when given after a first treatment failed.

The result, from a closely watched study called Evoke-01, will be seen as a disappointment by investors and oncologists alike.

Drugs like Trodelvy, known as antibody drug conjugates, are one of the hottest areas in oncology. The idea is that these medicines combine an antibody, which is triggered when it binds to a protein on a cancer cell, with a “payload” of chemotherapy that poisons the cancer.

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： United colonoscopy coverage change 'may cost lives,' doctors say
Next article： Readout Newsletter: Bayer's future, Merck Caraway acquisition, etc

hotspot

WSS

Kenai launches with $82 million for Parkinson’s stem cell therapy

David Sabatini, ex

Abortion pill mifepristone to soon be dispensed at CVS, Walgreens

Morphosys mixed study results for blood cancer drug

FogPharma raises $145 million in rare Series E round

Gain of function research would be limited under House proposal

hotspot

entertainment

entertainment

Medical leaders decry Supreme Court decision on affirmative action

Clinical trials giant ICON acquires HumanFirst

Hepatitis C has a cure — but many Americans still lack access to it

David Sabatini, ex

Peter Hotez and the public health issue of online harassment

Flu vaccine offering decent levels of protection this winter, new data show

At least 13 dead in Texas as scorching temps continue

How to fix the rural physician shortage in the U.S.

Anesthesiologist group: stop taking Ozempic before surgery

Kenai launches with $82 million for Parkinson’s stem cell therapy

hotspot

Kale crackers and hibiscus tea: My five days on a 'fasting diet'

In key trial, Verve's treatment lowers cholesterol levels in patients

RaDonda Vaught to speak at CommonSpirit event on patient safety

Wegovy, Zepbound and weight loss drugs that preserve muscle

Readout Newsletter: Bayer study halts, Carmot to IPO, and more

Why medical students are struggling with mental health

hotspot

leisure time

knowledge

hotspot